ArticleJournal of neuro-oncology2026
HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHER2 overexpression drives tumor aggressiveness and poor prognosis, serving as a crucial therapeutic target in various malignancies. While HER2’s role in breast cancer metastasis and prognosis is well-documented, its heterogeneity in brain metastases (BM) across different primary tumors remains understudied. This investigation examined HER2 status in matched primary cancers and BM across multiple cancer types to evaluate HER2 alterations during metastases.
methodsWe conducted a retrospective analysis of 185 matched primary tumor-BM pairs. HER2 expression was assessed using immunohistochemistry (IHC), with equivocal cases (IHC 2+) further evaluated by silver-enhanced in situ hybridization (SISH). We analyzed associations between HER2 positivity, clinicopathological factors, and survival outcomes.
resultsOf the 185 matched cases, lung, breast, and colorectal cancers were predominant, with breast cancer showing the highest HER2 positivity rate (61.5%, P < 0.001). HER2 positivity was detected in 14.1% (26/185) of primary tumors and 15.1% (28/185) of BM with a 7.6% (14/185) discordance rate between primary and metastatic sites. HER2 positivity in BM significantly correlated with age, primary cancer type, and BM location (P = 0.040, P < 0.001, P = 0.045, respectively). Age, BM location, BM size, BM multiplicity, and presence of other organ metastases were identified as independent prognostic factors.
conclusionsOur findings reveal significant HER2 heterogeneity between primary tumors and matched BM across cancer types. The observed discordance in HER2 status, particularly notable in breast cancer, underscores the necessity of HER2 status reassessment in BM for optimal targeted treatment strategies.
Indexed as
Identifiers
41718967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.